Philips expands peripheral vascular disease portfolio with the QuickClear mechanical thrombectomy system for blood clot removal

Rhea-AI Summary

Royal Philips announces the launch of the QuickClear Mechanical Thrombectomy System, a single-use, all-in-one catheter and pump designed for removing blood clots from peripheral vessels. This system simplifies procedures, eliminating the need for capital equipment, and features a compact design with high aspiration power. Recently cleared by the U.S. FDA, the system aims to provide cost-effective solutions in both hospital and outpatient settings. Philips plans further geographical expansion for this innovative device, enhancing its vascular treatment portfolio.

Positive

• QuickClear system received U.S. FDA 510(k) clearance, enhancing product portfolio.
• Innovative design reduces capital costs and supports faster procedures.
• Compact size provides high aspiration power, improving workflow efficiency.

Negative

• None.

September 24, 2020

• Powerfully simple thrombectomy solution provides physicians with an all-in-one, single-use aspiration catheter and pump system
• Intuitive design eliminates the need for capital equipment, with easy setup supporting faster procedures times
• Significantly smaller footprint provides the same or greater aspiration power as currently-available thrombectomy devices [1]      
  

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the innovative QuickClear mechanical thrombectomy system. The compact, single-use system provides an all-in-one aspiration pump and catheter for the removal of blood clots from the vessels of the peripheral arterial and venous systems [2]. The system’s innovative all-in-one design is simple to use while eliminating the need for capital equipment or costly accessories, with easy setup supporting faster procedures times. The Philips QuickClear Mechanical Thrombectomy System has received U.S. FDA 510(k) clearance and is available for sale in the U.S.

“This novel thrombectomy system is the latest addition to Philips’ market-leading portfolio for the diagnosis and treatment of peripheral vascular diseases,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “Its intuitive design simplifies the entire thrombectomy procedure workflow. By taking away the high initial capital expenditure costs associated with traditional mechanical thrombectomy systems, QuickClear can help bring cost-effective solutions to both the hospital and outpatient care settings.”

Simple, optimized performance
QuickClear simplifies the entire thrombectomy procedure workflow. The small footprint of the sterile device allows it to be placed easily and conveniently on the table next to the patient. With the touch of a button, the system is up and running at maximum aspiration power within seconds. The consistency of the aspiration power during the procedure provides physicians more control and supports faster procedure times. The system’s range of catheters includes a large 10F aspiration catheter, providing 59% more aspiration volume than 8F aspiration catheters [1].

“QuickClear is a simple and easy to use mechanical thrombectomy system,” said Bryan Fisher, MD, Chief of Vascular Surgery, Tristar Centennial Medical Center, Nashville, U.S. “The system is significantly smaller than other systems without compromising aspiration power. The convenience of the device really shines through with its single use and lack of capital equipment. I am excited about the potential of this device and the impact it will have on my practice and the patients I treat.”

Philips’ peripheral vascular portfolio already includes advanced interventional imaging systems for precision guidance; intravascular ultrasound (IVUS) catheters to assess the location of the disease and lesion morphology and guide and confirm the treatment; peripheral atherectomy devices to remove blockages; and peripheral therapy devices, such as Philips’ Stellarex drug-coated balloon, to treat lesions. Philips recently further extended this portfolio with the acquisition of Intact Vascular, maker of the Tack Endovascular System, a first-of-its-kind, minimal-metal, dissection repair device that provides precision treatment of peripheral arterial dissections following balloon angioplasty in above-the-knee (ATK) and below-the-knee (BTK) therapeutic interventions.

New Cardiovascular Horizons digital symposium
Today, September 24^th at 19:00 ET Philips will host a symposium entitled ‘QuickClear Mechanical Thrombectomy System: A Powerfully Simple and Cost-Effective Solution’ as part of the New Cardiovascular Horizons (NCVH) digital education series. To register, visit here.

The Philips QuickClear Mechanical Thrombectomy System is U.S. FDA 510(k) cleared and available for sale in the U.S., with future expansion of availability to other geographies planned.

[1] Testing performed in-house. Data on file.
[2] The Philips QuickClear mechanical thrombectomy system is indicated for the removal of soft, fresh emboli and thrombi from the vessels of the peripheral arterial and venous systems.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com

Twitter: mark_groves

Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31 622 698 001
Email: fabienne.van.der.feer@philips.com

Twitter: FC_Feer

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips QuickClear mechanical thrombectomy system in hand
• Philips QuickClear mechanical thrombectomy system in use

FAQ

What is the QuickClear Mechanical Thrombectomy System by Philips?

The QuickClear system is a compact, single-use device designed for efficiently removing blood clots from peripheral arterial and venous systems.

When was the QuickClear Mechanical Thrombectomy System announced?

The QuickClear system was announced on September 24, 2020.

What does the FDA clearance for QuickClear mean?

The FDA clearance confirms that the QuickClear Mechanical Thrombectomy System meets safety and efficacy standards for use in the U.S.

How does the QuickClear system benefit hospitals and outpatient settings?

It eliminates the need for costly capital equipment, simplifying setup and enabling faster patient procedures.

What are the future plans for the QuickClear system's availability?

Philips plans to expand the availability of the QuickClear system to additional geographies beyond the U.S.